RaySearch Laboratories AB is pleased to announce that the strategic partnership with BEBIG Medical, which began in 2018, has been extended through a memorandum of the agreement.
RaySearch expands collaboration with BEBIG Medical Read More »
Biophytis SA announced that it has submitted the application for Clinical Trial Authorization to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA.
150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction or intensive reinduction in the 2nd, 3rd, or 4th salvage of AML and the 1st interim analysis of this study shall be done for NDA approval to the FDA in US soon after
Beckman Coulter, a clinical diagnostics leader, unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint.
Rona Therapeutics, Inc and Keymed Biosciences, announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis.
Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for IBI351 for the treatment of previously treated advanced colorectal carcinoma patients with KRASG12C mutation.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 for patients diagnosed with a microorganism infection.
Athenex, Inc. announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division, Orascovery, and Cell Therapy.
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process Read More »
Catalent, Inc. announced it will be postponing the release of its financial results for the third quarter of fiscal year 2023, ended March 31, 2023, and the conference call previously scheduled for Monday, May 15, 2023 at 8:15 a.m.
Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call Read More »
The FDA has four events lined up this week, including a target action date for Krystal Biotech’s gene therapy for a rare skin disease and an adcomm meeting for Pfizer’s RSV vaccine candidate.
FDA Action Alert: Krystal, Genmab/AbbVie, Pfizer and Intercept Read More »
